Article Text

Download PDFPDF
Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer
  1. Divya Natesan, BS*,
  2. Julian C. Hong, MD, MS*,
  3. Jonathan Foote, MD,
  4. Julie A. Sosa, MD, MA,§,
  5. Laura Havrilesky, MD, MHSc and
  6. Junzo Chino, MD*
  1. * Department of Radiation Oncology,
  2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Departments of
  3. Surgery and
  4. § Medicine, Duke Cancer Institute, Duke Clinical Research Institute, Duke University School of Medicine, Durham NC.
  1. Address correspondence and reprint requests to Divya Natesan, BS, Department of Radiation Oncology, Duke Cancer Institute, 308 Durham, NC 27710. E-mail: divya.natesan{at}duke.edu.

Abstract

Objectives The objective of this study was to evaluate patterns of care and the survival impact of primary radiation and preoperative radiation therapy with surgery in women with locally advanced vulvar cancer using a large national cohort.

Methods and Materials Women with vulvar cancer, diagnosed from 2004 to 2012, who received primary or preoperative radiation therapy were identified in the National Cancer Database. Patient characteristics, such as age, race, American Joint Committee on Cancer stage, and comorbidity score, were compared between those that received primary radiation only and those that received preoperative radiation with surgery using the χ2, Fisher exact, and Mann-Whitney tests as appropriate. Overall survival (OS) by treatment approaches was estimated via the Kaplan-Meier method and compared using the log-rank test. Factors associated with OS were determined using univariate and multivariate Cox proportional hazards regression models.

Results A total of 2046 women were identified; 1407 of these women (69%) received primary radiation therapy (RT; n = 421) or chemoradiation therapy (CRT; n = 986) (RT/CRT), and 639 women (31%) received preoperative RT (n = 92) or CRT (n = 547) followed by surgery (RT/CRT + S). The American Joint Committee on Cancer staging distributions were as follows: T1 (n = 152), T2 (n = 1436), T3 (n = 405), N0 (n = 899), N1 (n = 480), N2 (n = 445), and N3 (n = 40). Median follow-up was 21.9 months. Primary RT/CRT was associated with compromised OS, compared with preoperative RT/CRT + S (41.7% vs 57.1% at 3 years, respectively; P < 0.001). On multivariate analysis, OS associated with primary RT/CRT with doses more than 55 Gy was not significantly different from RT/CRT + S (hazards ratio, 1.139; 95% confidence interval, 0.969–1.338; P = 0.116). Use of concurrent chemotherapy improved OS of primary RT with doses more than 55 Gy compared with CRT + S (hazards ratio, 1.107; 95% confidence interval, 0.919–1.334; P = 0.234).

Conclusions In a large nationwide analysis, primary nonsurgical management of vulvar cancer with RT was associated with compromised survival compared with preoperative RT with surgery. However, with doses more than 55 Gy and concurrent chemotherapy, nonoperative approaches had comparable survival compared with preoperative CRT + S.

  • Vulvar cancer
  • Chemoradiation
  • Definitive therapy
  • NCDB

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.